share_log

沃尔夫研究上调快而精医药(QGEN.US)至买入评级,目标价50美元

Wolfe Research Upgrades Qiagen NV(QGEN.US) to Buy Rating, Announces Target Price $50

Futu News ·  Jun 27 17:33  · Ratings

Wolfe Research analyst Doug Schenkel upgrades $Qiagen NV (QGEN.US)$ to a buy rating, and sets the target price at $50.

According to TipRanks data, the analyst has a success rate of 65.6% and a total average return of 26.9% over the past year.

AnalystRecentRatingAutoNews_203800_20240627_ee901034e89e5e1c6b3a89dfac097daa5e58a89f_1719491496485991_nn_en

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment